More on $CLRB
Here is a new article on CLRB that I found today on the web. Don't know who this guy is, but he is VERY bullish! Here's the first part of the article:
Cellectar Biosciences' PDC Delivery Platform May Advance Treatment of Multiple Myeloma
GuruFocus.com
February 14, 2017
- By Joshua Rodriguez
Cellectar Biosciences Inc. (CLRB), a Madison, Wisconsin-based oncology company, is generating a tremendous amount of industry interest with its Phospholipid Drug Conjugate (PDC).
The PDC is a proprietary platform that enables delivery of diverse oncologic payloads through its phospholipid ether cancer-targeting vehicle. Importantly, not only does the company's unique PDC platform provide a targeted therapeutic treatment, it also increases the therapeutic payload of the drug directly to cancer cells, which enhances effectiveness and reduces drug exposure to healthy cells, potentially reducing adverse events. These technological advantages within the company's PDC platform may act as the "secret sauce" that opens the door to tremendous opportunities for both Cellectar and its investors.
Since first writing about Cellectar, investors have pinged me on several occasions asking for a review of the most recent phase I data of their Multiple Myeloma drug, CLR 131, and to provide some analysis as to where I believe the already impressive data may ultimately lead. But, if I were to do so and not include the opinion that the PDC technology generating these impressive results was the most seducing part of the Cellectar Biosciences equation, I would be selling the investment world short. And short, by the way, is not a position I would currently recommend in regard to Cellectar's stock ownership.
PDC, better than a basket of wings
Cellectar is providing striking results in treating both relapsed or refractory multiple myeloma, combined with a safety and tolerability profile that is extremely encouraging when compared to current standards of care. The overall survival rate and patient tolerability results already demonstrated with single, lower dose treatments may ultimately put CLR 131 toward the top of the efficacy list.
With the essential basics out of the way, it is time to dig deep into this PDC platform. It is a crucial component to what they are doing. While the PDC platform is currently being used to generate some mouthwatering results in its current clinical trials, the applications to which it can be applied are much broader than treating multiple myeloma, although such an accomplishment will be a great way to put an exclamation point on its proof of concept.
Cellectar and strategy
Cellectar is deep into the process of providing proof of concept for its PDC platform, continuing its CLR 131 franchise and advancing early-stage development chemotherapeutic conjugates so that when applied through the PDC process, they can achieve significantly higher therapeutic benefits for patients.
Unlocking the power exuding from the platform is key because once it is established as a breakthrough technology, its use in delivering a targeted therapeutic dose of treatment will be applicable through a wide range of cancer-targeting therapies. This is the "protein" within the company, and like all good high-protein meals, it could make Cellectar extremely strong.
The basis for the PDC delivery platform is to deliver a phospholipid ether cancer-targeting vehicle, exploiting selective cancer and cancer stem cells, allowing for the uptake and prolonged retention in malignant cells. By being able to attach to a diverse set of oncologic payloads, the PDC platform may prove to have the ability to treat a broad range of cancer indications.
* [New drug platforms that have applications to various situations provide huge upside potential for the company because of the possibility of many many licensing opportunities with different companies to make use of the platform to improve the efficacy of their own drugs.] *
While I want you to take my word as to the platform's merit, it is worth it to acknowledge two peer-reviewed publications that offer extensive research and scientific validation of PDC. In an article published by Nature Reviews Clinical Oncology titled "Beyond The Margins: Real Time Detection of Cancer Using Targeted Fluorophores," the review team evaluated the current use of fluorescent molecules in cancer diagnostics as well as the fluorescence-guided surgical resection of tumors. The report focused on the need for the use of targeted delivery of molecules to malignant tissue. The peer-reviewed data in both reports was consistent in several conclusions, but one clearly stands out to benefit Cellectar: both journals provided insight, review and validation of the unique potential and varied utility of its PDC platform. With this validation comes the increased likelihood of partnership and licensing opportunities as the company continues to mature the pipeline.
*****************************************************************
To read the rest of the article, go to this link:
finance.yahoo.com/news/cellectar-biosciences-pdc-delivery-platform-205418085.html
Also please note:
There is a link in the article to an article on gurufocus.com about 4 serious warning signs with CLRB. I couldn't access it as it requires a paid subscription.
Again, not sure about how immediate the share price appreciation will be so for short term traders, I don't know how interesting it will be, but for those with a 6 mths to a year horizon, I think there should be significant opportunity for appreciation. After Cohort 3 results are reported, and if positive, that will move the stock. Phase II is also beginning. Take a look at their presentation to see upcoming catalysts.
CLRBZ warrants were down a bit today. A great entry point I think - certainly cheaper than where I bought.
